DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: adalimumab
Other: placebo

First Posted Date: 2015-07-16

Last Posted Date: 2019-01-04

Lead Sponsor: AbbVie

Target Recruit Count: 205

Registration Number: NCT02499783

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Phase 2

Completed

Conditions: Hepatitis C (HCV)
Hepatitis C Genotype 1a
Chronic Hepatitis C

Interventions: Drug: Ombitasvir/ABT-450/Ritonavir
Drug: Dasabuvir
Drug: Ribavirin (RBV)

First Posted Date: 2015-07-10

Last Posted Date: 2017-10-31

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT02493855

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Phase 2

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: Ombitasvir mini tablet
Drug: Ombitasvir/paritaprevir/ritonavir
Drug: Paritaprevir mini tablet
Drug: Dasabuvir
Drug: Ritonavir mini tablet
Drug: Ribavirin
Drug: Dasabuvir mini tablet
Drug: Ribavirin solution

First Posted Date: 2015-07-01

Last Posted Date: 2021-10-05

Lead Sponsor: AbbVie

Target Recruit Count: 64

Registration Number: NCT02486406

Locations: 🇵🇷
San Jorge Children Hospital /ID# 136832, San Juan, Puerto Rico
🇺🇸
Seattle Children's Hospital /ID# 137019, Seattle, Washington, United States
🇩🇪
Helios Klinikum Wuppertal /ID# 142883, Wuppertal, Germany

and more 18 locations

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: ombitasvir/paritaprevir/ritonavir

First Posted Date: 2015-07-01

Last Posted Date: 2017-12-04

Lead Sponsor: AbbVie

Target Recruit Count: 18

Registration Number: NCT02487199

Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients

Completed

Conditions: Parkinson Disease (PD)

First Posted Date: 2015-06-30

Last Posted Date: 2021-06-25

Lead Sponsor: AbbVie

Target Recruit Count: 88

Registration Number: NCT02485600

Locations: 🇨🇦
Hamilton Health Sciences /ID# 148808, Hamilton, Ontario, Canada
🇨🇦
St. Boniface Clinic, CA /ID# 162092, Winnipeg, Manitoba, Canada
🇨🇦
Kingston General Hospital /ID# 144942, Kingston, Ontario, Canada

and more 10 locations

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: veliparib
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2015-06-26

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 9

Registration Number: NCT02483104

Locations: 🇯🇵
Site Reference ID/Investigator# 128815, Kurume-shi,Fukuoka, Japan
🇯🇵
Site Reference ID/Investigator# 128058, Nagaizumi-cho, Japan
🇯🇵
Site Reference ID/Investigator# 128997, Morioka-shi, Japan

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Phase 3

Completed

Conditions: Hepatitis C Genotype 1a
Chronic Hepatitis C
Hepatitis C (HCV)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir
Drug: dasabuvir
Drug: ribavirin

First Posted Date: 2015-06-19

Last Posted Date: 2017-10-03

Lead Sponsor: AbbVie

Target Recruit Count: 25

Registration Number: NCT02476617

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

Terminated

Conditions: Ovarian Cancer
Ovarian Neoplasm

Interventions: Drug: Paclitaxel
Drug: Veliparib
Drug: Carboplatin
Other: Placebo to Veliparib

First Posted Date: 2015-06-12

Last Posted Date: 2024-10-26

Lead Sponsor: AbbVie

Target Recruit Count: 1140

Registration Number: NCT02470585

Locations: 🇺🇸
Sinai Hospital of Baltimore /ID# 141306, Baltimore, Maryland, United States
🇺🇸
The Ohio State University - Columbus /ID# 138053, Columbus, Ohio, United States
🇺🇸
Fox Chase Cancer Center /ID# 149479, Philadelphia, Pennsylvania, United States

and more 207 locations

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: ABBV-838
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2015-06-04

Last Posted Date: 2018-09-13

Lead Sponsor: AbbVie

Target Recruit Count: 74

Registration Number: NCT02462525

Locations: 🇺🇸
Washington University School of Medicine /ID# 135708, Saint Louis, Missouri, United States
🇺🇸
Mount Sinai Medical Center /ID# 133569, New York, New York, United States
🇺🇸
The University of Chicago Medical Center /ID# 139403, Chicago, Illinois, United States

and more 16 locations

An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)

Completed

Conditions: Crohn's Disease
Rheumatoid Arthritis
Psoriasis

First Posted Date: 2015-05-22

Last Posted Date: 2019-06-19

Lead Sponsor: AbbVie

Target Recruit Count: 168

Registration Number: NCT02451839

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy